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Abstract: Background and aims: The aim of this study was to explore potential associations of the intron 4 variable number of tandem repeats
(VNTR) and E298A polymorphisms of the endothelial nitric oxide synthase (eNOS) gene with slow coronary flow (SCF). The association between
plasma nitrate and nitrite (NOx) concentrations and eNOS gene polymorphisms was also assessed.Materials and methods: The intron 4 VNTR and
E298A polymorphisms of the eNOS gene were evaluated in the isolated DNA blood samples obtained from the SCF patient group (n= 30) and
healthy group consisted of age- and sex-matched controls (n= 61). Results: Plasma NOx level was significantly lower in patients with SCF than in
controls. In addition, patients with SCF have significantly lower nitric oxide levels than control subjects within each genotype variants. The allele and
genotyped frequencies of the eNOS intron 4 VNTR and E298A polymorphisms were similar between patients with SCF and the controls. Plasma
NOx concentrations with respect to the relevant genotypes were found insignificant. Discussion and conclusion: Plasma NOx is lower in patients with
SCF than in healthy subjects. Our findings may suggest the lack of association between intron 4 VNTR and E298A polymorphisms of the eNOS gene
and SCF.
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Introduction
Nitric oxide (NO) is one of the most important mole-
cules that are responsible for the vasodilator tone
required for the regulation of blood pressure [1]. NO
is synthesized from L-arginine by a family of enzymes,
the NO synthases (NOSs; EC 1.14.13.39), through the
L-arginine/NO pathway [2]. There are at least three
isoenzymes of NOS, namely inducible NOS, neuronal
NOS, and endothelial NOS (eNOS) [3]. The gene
encoding eNOS is located on chromosome 7q35–36
and comprises 26 exons spanning 21 kb [4]. The
basal release of NO by endothelium inhibits platelet
aggregation [5], antagonizes vascular smooth muscle
cell proliferation [6], and attenuates platelet and leuko-
cyte adhesion [7–9]. All of these processes are important
events during atherogenesis. Thus, the association of a
subset of eNOS genotype with cardiovascular disease has
extensively been screened. Among the reported poly-
morphisms of the eNOS gene, a significant association of
intron 4 variable number of tandem repeats (VNTR)
polymorphism of the eNOS gene with coronary artery
disease has been reported [10]. In addition, E298A
polymorphism in exon 7 of the eNOS gene was reported
to be associated with coronary artery spasm [11]. The
effects of aforementioned polymorphisms on in vivoNO
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generation cannot be directly measured because most
endogenous NO rapidly oxidizes to nitrite (NO2
−) and
is eventually converted to nitrate (NO3
−). Collectively,
these inactive metabolites (nitrite and nitrate, termed
as NOx) have been used to reflect endogenous NO
production.
Slow coronary flow (SCF), characterized by slow
antegrade progression of a dye to the distal branch of
a coronary artery in the absence of obstructive coronary
disease, is not an infrequently detected finding during
routine coronary arteriography [12].
Yet, the precise pathophysiological mechanisms of
SCF remain uncertain. The imbalance between vaso-
constrictor and vasodilator factors has previously been
proposed as one of the possible mechanisms for SCF
[13]. We also reported decreased NO levels in patients
with SCF [14]. Thus, we planned this study in an
attempt to delineate potential associations of the intron
4 VNTR and E298A polymorphisms of the eNOS gene
and SCF.
Materials and Methods
Patients
The study population consisted of 30 patients with
SCF and 61 control subjects with normal coronary
flow. All participants were selected from among those
who had undergone coronary arteriography. The
majority of the subjects were suffering from intractable
symptoms, such as angina and angina-like symptoms,
shortness of breath, palpitations, and their symptoms
could not be adequately clarified with non-invasive
tests. All the patients who have SCF and do not have
any other cardiac diseases such as coronary artery
disease and heart failure were selected as patient group.
Coronary arteriographies were performed by the same
team and the definition of SCF was determined in
accordance with the thrombolysis in myocardial infarc-
tion (TIMI) frame count (TFC) method as previously
described [15].
Fasting blood samples were obtained 2months after the
coronary arteriography. From the blood samples, DNA
was extracted by the phenol/chloroform method using
the leukocyte fraction. For NO determination, plasma
samples were stored frozen at −30 °C. Biochemical
parameters were determined by enzymatic methods
(Modular DP, Roche Diagnostics, Mannheim, Germany).
Laboratory tests were performed without knowing coro-
nary arteriographic data. All of the participated patients
were requested to sign the written informed consent
form regarding the study protocol of this study that has
been approved by the Ethics Committee of Başkent
University, including the blood sample collection for DNA
analysis.
Genotyping
After obtaining the blood samples, genomic DNA was
prepared from leukocyte pellets by sodium dodecyl sul-
fate lysis, ammonium acetate extraction, and ethanol
precipitation [16]. It was then used as a template for
polymerase chain reaction (PCR) analysis, as previously
described by Yoon et al. [17].
eNOS gene intron 4 VNTR genotyping
PCR products were separated by electrophoresis on a 2%
agarose gel and identified by ethidium bromide staining.
The products for the b and a alleles were 420 and 393 bp,
respectively. Thus, each DNA sample revealed one of the
three possible patterns at the end of electrophoresis: a
420-bp band (bb genotype), a 393-bp band (aa geno-
type), or both the 420-bp and the 393-bp bands (ab
genotype) [18].
eNOS gene E298A genotyping
A 152-bp-amplified fragment was digested with BanII.
The G allele consisted of 56 and 96 bp. Restriction site is
lost in the case of G-to-T substitution [19].
NO analysis
Plasma nitrite concentration was accepted as an index of
NO. For total nitrite detection, deproteinized plasma was
treated with copperized cadmium granules to reduce
NO−3 to NO−2. Nitrite concentrations were quantified
by a colorimetric assay based on the Griess reaction [20].
Briefly, a chromophore with strong absorbance at 545 nm
is formed by the reaction of nitrite with a mixture of
N-(1-naphthyl)ethylenediamine and sulfanilamide. A
standard curve was established with a set of serial dilutions
(10−8–10−3 mol/L) of sodium nitrite. The results are
expressed as micromoles per liter of plasma (μmol/L).
Statistical analysis
Data analyses were performed using the Statistical
Package for the Social Sciences, version 13.0 (SPSS
Inc., Chicago, IL, USA). Data are expressed as
mean ± standard error of the mean (SEM). Homogene-
ities of data set were controlled by Levene’s test. Nor-
mality of distribution of variables was controlled by
Shapiro–Wilk test. Continuous variables with normal
distribution were analyzed by unpaired t-test. When
parametric test assumptions were violated, the compar-
isons of the variables were carried out by Mann–Whitney
U test or Kruskal–Wallis test. Kruskal–Wallis test was
followed by Dunn’s test for multiple comparisons. The
relationships between categorical variables were statisti-
cally evaluated by χ2 test, Fisher’s exact test for 2 × 2
tables, and G-test. G-test was used because of the zero
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values and small frequencies in the some cells of the
contingency tables. p values less than 0.05 were consid-
ered statistically significant.
Results
Table I shows the clinical characteristics of the study
population. There were no significant differences be-
tween patients with SCF and controls with respect to
age, prevalence of hypertension and diabetes, smoking
habits, and body mass index. The biochemical parameters
were also similar between groups. But, patients with SCF
had higher low-density lipoprotein cholesterol and lower
NOx blood levels than the controls.
The allele and genotyped frequencies of the eNOS
intron 4 VNTR and E298A polymorphisms in patients
with SCF and control subjects are shown in Table II.
The distributions of the eNOS gene were insignificant
between patients with SCF and controls.
All subjects were genotyped for eNOS gene E298A;
the frequencies of the G/G, G/T, and T/T genotypes
were 0.367 (11/30), 0.433 (13/30), and 0.20 (6/30) in
patients with SCF, and 0.311 (19/61), 0.41 (25/61),
and 0.279 (17/61) in the controls, respectively. The
genotype distribution for intron 4 VNTR revealed that
among 30 patients with SCF, 24 had b/b (0.80), 6 had
b/a (0.20), and none had a/a. Among 61 healthy sub-
jects, 46 had b/b (0.754), 14 had b/a (0.23), and 1 had
a/a genotype (0.016).
The plasma NOx level was lower in patients with SCF
than in control subjects (41.93 ± 11.5 vs. 49.81 ± 10.74,
p < 0.001). NOx concentrations with respect to the
genotypes of the polymorphism are shown in Table III.
For each genotype variants, patients with SCF had sig-
nificantly lower NO levels than control subjects. Plasma
Table I Clinical and biochemical characteristics of the study subjects
Control subjects (n= 61) Patients with SCF (n= 30)
Mean ± SEM Mean ± SEM
Median (min–max) Median (min–max) p
Age (years) 56.2 ± 1.06 54.27 ± 7.34 ns
55 (35–73) 54 (41–74)
NO (μmol/L) 49.81 ± 1.38 41.93 ± 2.1 <0.001
48.08 (33.3–98.79) 40.52 (30.71–81.06)
Glucose (mg/dL) 107.8 ± 5.81 100.93 ± 3.74 ns
97 (78–349) 99.5 (70–197)
BUN 14.69 ± 0.45 17.1 ± 1.29 ns
14 (8–24) 16.5 (7–42)
Cre 0.95 ± 0.03 1.11 ± 0.06 <0.01
0.92 (0.4–2.26) 1.08 (0.65–2.26)
Chol 175.02 ± 3.04 177.03 ± 5.22 ns
178 (117–226) 171.5 (128–244)
HDL-C 43.21 ± 0.92 47.57 ± 2.26 <0.05
43 (18–60) 47.5 (30–99)
LDL-C 98.05 ± 2.57 110.4 ± 4.27 <0.001
98 (22–149) 109 (43–164)
TG 133.39 ± 5.56 142.17 ± 11.46 ns
132 (46–311) 140.5 (70–318)
AST 18.21 ± 0.31 18.21 ± 0.85 ns
18 (12–27) 18 (11–34)
ALT 20.16 ± 0.64 20.97 ± 1.3 ns
20 (10–35) 19.5 (10–40)
SCF: slow coronary flow; NO: nitric oxide; BUN: blood urea nitrogen; Cre: creatine; Chol: total cholesterol; TG: triglycerides; HDL-C and LDL-C:
high-density lipoprotein cholesterol and low-density lipoprotein cholesterol; AST: aspartate transaminase; ALT: alanine transaminase; ns: not
significant
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NO concentrations with respect to the genotypes of the
polymorphisms were found not to be significantly differ-
ent as shown in Figs 1 and 2.
Discussion
This study has examined the impact of intron 4 VNTR
and E298A genotype of the eNOS gene in SCF. The
findings of this study may suggest that there exist no
particular association between the relevant polymorph-
isms of eNOS gene and SCF in our population.
The mechanisms of the imbalance between vasocon-
strictor and vasodilator factors have been proposed for
slow coronary flow phenomenon (SCFP) [13, 14, 21].
Previous studies have highlighted the imbalance between
endothelin-1 and NO release in patients with SCF as
compared with controls with normal coronary flow [21].
Endothelin-1 and NO are the important molecules that
modulate vasodilatory response to stress. There is also
growing body of evidence indicating that a deficit of NO
production causes endothelial dysfunction. Endothelial
dysfunction may be regarded as an early contributor to
atherogenesis and development of SCF as well [22]. A
family-based study has demonstrated a significant linkage
between the level of plasma metabolites of NO and
markers located in the region of the eNOS gene, suggest-
ing that variation in the eNOS gene sequence might affect
NO production [23]. In line, Tsukada et al. [24] found a
strong association between intron 4 VNTR polymor-
phism of the eNOS gene and plasma NO metabolite
levels. Yoon et al. [17] also reported that the E298A
polymorphism of the eNOS gene was associated with
increased plasma NOx levels. In addition, Veldman et al.
[25] demonstrated that the presence of an Asp allele of
the eNOS E298A polymorphism is associated with a
reduced basal NO production. Given the importance of
NO as a cardiovascular mediator, it is conceivable that
polymorphisms of the eNOS gene could be associated
with pathophysiological manifestations affecting cardio-
vascular system including SCFP.
Table II Frequencies of the alleles and genotypes of the Glu298Asp
and the VNTR a/b in patients with SCF and control
subjects
Control subjects
(n= 61)
Patients with
SCF (n= 30)
Variable n (%) n (%) p
Alleles
T 59/122 (48.4) 25/60 (41.7) ns
G 63/122 (51.6) 35/60 (58.3) ns
4b 107/122 (87.7) 53/60 (88.3) ns
4a 15/122 (12.3) 7/60 (11.7) ns
Genotypes
T/T 17/61 (27.9) 6/30 (20.0) ns
T/G 25/61 (41) 13/30 (43.3) ns
G/G 19/61 (31.1) 11/30 (36.7) ns
4b/b 46/61 (75.4) 24/30 (80.0) ns
4b/a 14/61 (23.0) 6/30 (20.0) ns
4a/a 1/61 (1.6) 0/30 (0.0) ns
Table III Comparison of mean plasma NOx levels between the genotypes of eNOS polymorphisms in patients with SCF and control subjects
NOx (μmol/L)
Control subjects (n= 61) Patients with SCF (n= 30)
Mean ± SEM Mean ± SEM
Median (min–max) Median (min–max) p
E298A
T/T 47.86 ± 2.57 37.22 ± 2.77 <0.05
45.51 (33.3–72.15) 36.63 (30.71–48.84)
G/T 49.08 ± 2.33 41.45 ± 2.41 <0.05
47.36 (34.78–98.79) 41.81 (30.71–53.28)
G/G 52.49 ± 2.21 45.07 ± 4.72 <0.01
48.47 (39.96–81.4) 41.36 (31.08–81.06)
Intron 4
4b/b 48.74 ± 1.47 42.4 ± 2.27 <0.01
47.72(33.3–98.79) 41.26 (30.71–81.06)
4b/a 52.54 ± 3.45 40.07 ± 5.7 <0.05
47.73 (35.15–81.4) 35.15 (30.71–66.97)
Sezgin et al.
ISSN 2061-1617 © 2017 The Author(s) 120 Interventional Medicine & Applied Science
Up to date, eNOS single-nucleotide functional 786
T–C [26, 27], Glu298Asp [28], and intron 4a/b eNOS
[29] have been evaluated in patients with SCF in Turkish
population. Nurkalem et al. [26] reported an increased
prevalence of the CC/CT genotypes (particularly the CT
heterozygote) in patients with the SCF and noted that the
C allele was weakly correlated with the extent of slow flow
as measured by the TFC. In contrast, in a recent study,
Gazi et al. [27] found no relationship between T-786 T–C
polymorphism and SCFP. Consistent with the results of
this study, Caglayan et al. [28] showed that Glu298Asp
polymorphism is not associated with SCF in Turkish
population. In contrast to our results, Ekmekçi et al.
[29] reported that in patients with SCF, the “a allele” of
ecNOS intron 4 VNTR is an independent predictor of the
SCF (odds ratio 3.22, 95% confidence interval 1.28, 8.82)
and is associated with an impaired coronary flow reserve. In
this study, the distribution of genotypes calculated by
direct counting of “a” and “b” alleles was insignificant
between patients with SCF and controls. This study pop-
ulation included only a small number of patients, which
could have been the cause of the different results.
Recently, Gupta et al. [30] examined the Glu298Asp
and intron 4 VNRTNOS polymorphisms in patients with
SCF in Indian population. In contrast to our and previous
studies [27], the authors reported strong association
between the Glu298Asp eNOS polymorphism and
patients with SCF. Similar to this study, but in contrast
to the previous study [29], they did not observe an
association between the “a allele” and the SCF. However,
somewhat surprisingly and in contrast to the previous
studies [13, 14, 21], the plasma NO levels were elevated
in patients with SCF compared with controls and in-
creased with respective genotype. The authors explain the
divergence in their results compared with previous studies
as being attributable to (1) racial differences between
Indian and Turkish patients and (2) the increased NO
levels not necessarily reflecting differences in NO activity.
Finally, it should be appreciated that endothelial dys-
function is not the sole-proposed pathophysiological
mechanism of SCF. There are several other hypotheses
that have been suggested [31, 32].
Our findings are limited due to the fact that it was
based on relatively few individuals who were all Cauca-
sians. Larger sample sizes involving patients with different
ethnicities are warranted.
Conclusion
In conclusion, our findings are suggestive of lack of
association between intron 4 VNTR and E298A poly-
morphisms of the eNOS gene and SCF.
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Fig. 1. The differences between the genotypes of eNOS polymor-
phism (intron 4 VNTR) with respect to plasma NOx levels
Fig. 2. The differences between the genotypes of eNOS polymor-
phism (exon 7 E298A) with respect to plasma NOx levels
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